ASCO is co-sponsoring the “Accelerating Anticancer Agent Development and Validation Workshop.” A postgraduate workshop for clinical and translational investigations focused on strategic planning to develop and validate new anticancer and cancer prevention agents and pathways. This is an intensive and interactive workshop in how to design effective strategies - from clinical trial initiative, to enabling trials, to pivotal efficacy trials - leading to the development of new anticancer and prevention agents.  The course is taught by a distinguished faculty from across the academic, industry, consumer, and government (FDA) sectors.

May 16-18, 2012
Bethesda North Marriott Hotel and Conference Center
North Bethesda, MD 

Registration is now open
Registration Fee: $1375* Scholarships available for qualified academic, advocate and government applicants. 

Background:
The Accelerating Anticancer Agent Development and Validation Workshop is designed to bring together leaders in clinical and translational cancer research from academia, industry, NCI, and FDA to assist investigators in understanding and improving the process of cancer drug development. This three-day collaborative workshop will provide a “small group” atmosphere where participants will have the option of bringing to this workshop an agent or strategy with promising early-stage clinical data for discussion. An FDA representative, a biostatistician and an academic/industrial clinical investigator will be assigned to each small group to discuss learners' development strategies, including the potential pitfalls and the potential acceptability of the evidence produced by their strategy to support a new drug application (NDA). The strategic plans that the learners develop during the workshop will consider all feasible options and represent a scientifically sound, medically justified and FDA-consistent proposal for development. The small group sessions will be supplemented with lectures, roundtable breakout sessions and a “One-on-One with the Faculty” session.

Who Should Apply:
The Workshop is designed for scientists with clinical trial experience who have an interest in new approaches to developing or enhancing agents or combinations of agents for the diagnosis, treatment or prevention of cancer. Individuals with limited experience in the regulatory aspects of oncology drug development will benefit from this Workshop.

- A minimum of four years' of experience in drug development, either in an academic, industry or government agency setting 
- Minimum rank for academic applicants is assistant professor (postdoctoral students and fellows are not eligible) 
- Previous clinical trial experience as study investigator or participating physician at an approved site
- Academic applicants must have prior or current external, independent research support
- Industry applicants must hold a position on a drug development team
- For more information, please visit: http://www.acceleratingworkshop.org/who-should-register.php

Continuing Medical Education Activity: AMA PRA Category 1 Credits^TM available

Official Website:
For more information please visit: http://www.acceleratingworkshop.org/